Chemotherapy in NSCLC: a metanalysis using updated data on individual patients from 52 randomized clinical trials. NSCLC Collaborative Group. BMJ1995; 311: 899–909.
2.
SlevinM.L., StubbsL., PlantH.J.: Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ1990; 300: 1458–1460.
3.
TsevatJ., DawsonN.V., WuA.W. for the HELP Investigators: Health values of hospitalized patients 80 years or older. JAMA1998; 279: 371–375.
4.
ShepherdF.A., DanceyJ., RamlauR.: Prospective randomized trial of docetaxel versus best supportive care in patients with NSCLC previously treated with platinum-based chemotherapy. J Clin Oncol2000; 18, 2095–2103.
5.
ShepherdF.A., FossellaF.V., LynchT.: Docetaxel shows survival and quality of life benefits in the second line treatment of NSCLC: a review of two phase III trials. Semin Oncol2001; 28(Suppl 2): 4–9.
6.
SchuetteW., NagelS., SerkeM.: Second-line chemotherapy for advanced NSCLC with weekly versus three-weekly docetaxel: results of a randomized phase III study. Proc ASCO2004, 23: abst 7036.
7.
GridelliC., IllianoA., SalvagniS.: Effect on quality of life of weekly vs 3-weekly docetaxel in second-line treatment of advanced NSCLC. The DISTAL randomized phase III study. Proc ASCO2003; 22: 625a.
8.
DelbaldoC., MichielsS., SyzN.: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysisJAMA2004; 292: 470–484.
9.
FossellaF., PereiraJ.R., von PawelJ.: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced NSCLC: the TAX 326 study group. J Clin Oncol2003; 21: 3016–3024.
10.
GrallaR.J., RodriguesJ., von PawelJ.: Prospective analysis of quality of life in a randomized multinational phase III study comparing docetaxel plus either cisplatin or carboplatin with vinorelbine plus cisplatin in patients with advanced NSCLC. Proc ASCO2002; 21: 300a.
11.
FossellaF., BelaniC. for the TAX 326 Study Group: Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin for the first-line treatment of advanced/metastatic NSCLC: analysis in elderly patients. Proc ASCO2003; 22: abst 2528.
